AGA Clinical Trials

72 recruitingLast updated: May 11, 2026

There are 72 actively recruiting aga clinical trials across 33 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Bethesda, Maryland, United States, Philadelphia, Pennsylvania, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


AGA Trials at a Glance

72 actively recruiting trials for aga are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Not Applicable with 23 trials, with the heaviest enrollment activity in Bethesda, Philadelphia, and New York. Lead sponsors running aga studies include National Cancer Institute (NCI), Centre of Postgraduate Medical Education, and Simon Fraser University.

Treatments under study

About AGA Clinical Trials

Looking for clinical trials for AGA? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new AGA trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about AGA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 72 trials

Recruiting
Phase 1Phase 2

Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia

Androgenetic alopecia (AGA)Healthy Volunteers - Male and Female
Absci Pty Ltd.227 enrolled4 locationsNCT07317544
Recruiting
Not Applicable

Animal and Plant Proteins and Glucose Metabolism

Metabolic SyndromeGlucose Metabolism DisordersMetabolic Syndrome, Protection Against
University of Missouri-Columbia100 enrolled1 locationNCT03994367
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Not Applicable

Assessment of Stroke Volume and Cardiac Output in Response to Varying Heart Rates

Vasovagal Syncope
University of Calgary25 enrolled1 locationNCT03446326
Recruiting
Phase 1Phase 2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Not Applicable

Postural Sway and Counterpressure Maneuvers for Pediatric Syncope

Postural Orthostatic tachycardia SyndromeOrthostatic intoleranceSyncope, Vasovagal
Simon Fraser University30 enrolled1 locationNCT05633693
Recruiting
Not Applicable

Paediatric Syncope in the Emergency Department

Postural Orthostatic tachycardia SyndromeOrthostatic intoleranceSyncope, Vasovagal
Dr. Victoria Claydon300 enrolled1 locationNCT05555771
Recruiting
Not Applicable

The Effect of Water Carbonation on Orthostatic Tolerance

Orthostatic HypotensionSyncopeVasovagal Syncope
Simon Fraser University25 enrolled1 locationNCT05621460
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Pancreatic CancerHereditary Breast and Ovarian CancerHodgkin Lymphoma+43 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Phase 2

PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study

Androgenetic alopecia (AGA)
Nanfang Hospital, Southern Medical University76 enrolled1 locationNCT07335367
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+17 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Not Applicable

Hope Groups: Parenting and Mental Health Among Refugees in the Middle East

Mental HealthViolence Against Children
University of Oxford490 enrolled1 locationNCT07506421
Recruiting
Not Applicable

Promoting Physical Activity in Older Hispanic/Latino(a) Adults

Physical InactivitySedentary BehaviorAlzheimer Disease, Protection Against
Kaiser Permanente130 enrolled2 locationsNCT06362824
Recruiting
Phase 2

Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia

Androgenetic alopecia (AGA)
Shenzhen People's Hospital388 enrolled1 locationNCT07370519
Recruiting
Phase 2

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

Chagas Disease
Novartis Pharmaceuticals130 enrolled19 locationsNCT06632600
Recruiting
Not Applicable

Palestinian ParentText for Crisis

Mental HealthParentingViolence Against Children
University of Oxford250 enrolled1 locationNCT07494786
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024